I Hatlevoll1,2, L M Oldervoll3,4, A Wibe5,6, G B Stene7,8, S N Stafne3,9, E Hofsli7,5. 1. Department of Oncology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. ingunn.hatlevoll@stolav.no. 2. Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. ingunn.hatlevoll@stolav.no. 3. Department of Public Health and Nursing, Norwegian University of Science and Technology, Trondheim, Norway. 4. LHL-clinics, Trondheim, Norway. 5. Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway. 6. Department of surgery, St. Olav's Hospital, St. Olav's Hospital, Trondheim, Norway. 7. Department of Oncology, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway. 8. Department of Neuromedicine and Human Movement Science, The Faculty of Medicine and Health, Norwegian University of Science and Technology, Trondheim, Norway. 9. Department of Clinical Services, St. Olav's Hospital, Trondheim University Hospital, Trondheim, Norway.
Abstract
BACKGROUND:Colorectal cancer (CRC) is the third most common cancer worldwide, and a large proportion of the patients receive adjuvant oxaliplatin-based chemotherapy. Most of these experience chemotherapy-induced peripheral neuropathy (CIPN), affecting quality of life. Evidence to advise exercise to reduce CIPN is limited. The primary aim of this study was to investigate the feasibility of an exercise intervention and data collection among CRC patients during adjuvant chemotherapy. MATERIAL AND METHODS: This non-randomized feasibility study included CRC patients admitted to adjuvant chemotherapy to an intervention consisting ofsupervised aerobic endurance, resistance, and balance exercises twice a week at the hospital in addition to home-based exercise once a week. A physiotherapist supervised the patients, and the intervention lasted throughout the period of adjuvant chemotherapy (12-24 weeks). Participants performed physical tests and filled in questionnaires at baseline, 3, 6, 9, and 12 months. RESULTS AND CONCLUSION: Nineteen (63%) of 30 invited patients consented. A major barrier to recruit or consent to participation was long travel distance to the hospital. The completion rate of questionnaires and physical tests were near 100%. Seven participants dropped out, five before the intervention started. Median attendance to supervised exercise was 85%. There were no serious adverse events related to the intervention. Except for a planned higher intensity of endurance exercise, we found the intervention feasible and safe. Based on experiences in this study, some adjustments have been made for an upcoming randomized trial, including the supervised exercise taking place close to participants' homes. TRIAL REGISTRATION: NCT03885817, March 22, 2019, retrospectively registered.
RCT Entities:
BACKGROUND:Colorectal cancer (CRC) is the third most common cancer worldwide, and a large proportion of the patients receive adjuvant oxaliplatin-based chemotherapy. Most of these experience chemotherapy-induced peripheral neuropathy (CIPN), affecting quality of life. Evidence to advise exercise to reduce CIPN is limited. The primary aim of this study was to investigate the feasibility of an exercise intervention and data collection among CRCpatients during adjuvant chemotherapy. MATERIAL AND METHODS: This non-randomized feasibility study included CRCpatients admitted to adjuvant chemotherapy to an intervention consisting of supervised aerobic endurance, resistance, and balance exercises twice a week at the hospital in addition to home-based exercise once a week. A physiotherapist supervised the patients, and the intervention lasted throughout the period of adjuvant chemotherapy (12-24 weeks). Participants performed physical tests and filled in questionnaires at baseline, 3, 6, 9, and 12 months. RESULTS AND CONCLUSION: Nineteen (63%) of 30 invited patients consented. A major barrier to recruit or consent to participation was long travel distance to the hospital. The completion rate of questionnaires and physical tests were near 100%. Seven participants dropped out, five before the intervention started. Median attendance to supervised exercise was 85%. There were no serious adverse events related to the intervention. Except for a planned higher intensity of endurance exercise, we found the intervention feasible and safe. Based on experiences in this study, some adjustments have been made for an upcoming randomized trial, including the supervised exercise taking place close to participants' homes. TRIAL REGISTRATION: NCT03885817, March 22, 2019, retrospectively registered.
Authors: Cindy Tofthagen; Kristine A Donovan; Mary Ann Morgan; David Shibata; Yating Yeh Journal: Support Care Cancer Date: 2013-08-01 Impact factor: 3.603
Authors: Rutger H T Koornstra; Marlies Peters; Stacey Donofrio; Ben van den Borne; Floris A de Jong Journal: Cancer Treat Rev Date: 2014-02-07 Impact factor: 12.111
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Kristin L Campbell; Kerri M Winters-Stone; Joachim Wiskemann; Anne M May; Anna L Schwartz; Kerry S Courneya; David S Zucker; Charles E Matthews; Jennifer A Ligibel; Lynn H Gerber; G Stephen Morris; Alpa V Patel; Trisha F Hue; Frank M Perna; Kathryn H Schmitz Journal: Med Sci Sports Exerc Date: 2019-11 Impact factor: 5.411
Authors: Federica Duregon; Barbara Vendramin; Valentina Bullo; Stefano Gobbo; Lucia Cugusi; Andrea Di Blasio; Daniel Neunhaeuserer; Marco Zaccaria; Marco Bergamin; Andrea Ermolao Journal: Crit Rev Oncol Hematol Date: 2017-11-07 Impact factor: 6.312